reports
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand ...
Zealand Pharma launches long-term incentive programs for Zealand Pharm...
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the “LTIP...
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zold...
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). R...
- ABGSC Telecom Equipment Research
- Daniel Thorsson
- Øystein Elton Lodgaard
- Simon Granath
- ABGSC Shipping & Transport Research
- Mikkel Kousgaard Rasmussen
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Food & Beverage Research
- Mikkel Kousgaard Rasmussen
Molecular Partners presents three posters at AACR 2026, with new precl...
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic windowMP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE N...
- ABGSC Energy Research
- John Olaisen
Challenge accepted: Schneider Electric helps industry turn toughest pr...
Challenge accepted: Schneider Electric helps industry turn toughest problems into competitive advantage HANNOVER, Germany, April 19, 2026 (GLOBE NEWSWIRE) -- Industrial operations are under pressure from every direction. Energy costs are rising. Legacy systems are holding back progress. The talent pipeline is thinning. And the window to act is narrowing. At Hannover Messe 2026 (20–24 April, Hall 13, Booth C34), , a global energy technology leader, is showing what it looks like when those problems finally meet their match. Across five live areas — Operational Efficiency, Legacy Drag, the ...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
VALE.N VALE S.A. ADS
MKC MCCORMICK & COMPANY INCORPORATED
GSBD GOLDMAN SACHS BDC INC
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
CTAS CINTAS CORPORATION
CAG CONAGRA BRANDS INC.
BZUN BAOZUN INC SPONSORED ADR CLASS A
GAM GENERAL AMERICAN INVESTORS CO. INC.
SJW SJW GROUP
CULP CULP INC.
SCVL SHOE CARNIVAL INC.
CIA CITIZENS INC. CL A
FUL H.B. FULLER COMPANY
CRT CROSS TIMBERS ROYALTY TRUST
LW LAMB WESTON HOLDINGS INC.
NKE NIKE INC. CLASS B
PAGS PAGSEGURO DIGITAL LTD
FUND ROYCE FOCUS TRUST
FGBI INC.
NMM FIRST GUARANTY BANCSHARES
ENR NAVIOS MARITIME PARTNERS
SVC EDGEWELL PERSONAL CARE COMPANY
AIMD.P SERVICE PROPERTIES TRUST
CNXC AIM4 VENTURES
QFIN CONCENTRIX
VSCO 360 DIGITECH INC
SG VICTORIA'S SECRET & CO
HDB SWEETGREEN INC
IBRX HDFC BANK LTD
BEAT IMMUNITYBIO INC
MEGI HEARTBEAM INC
POCI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BPRN PRECISION OPTICS CORP INC (MASS)
LPCN BANK OF PRINCETON
HYMC LIPOCINE INC
BETR HYCROFT MINING HOLDING CORPORATION
BNR BETTER HOME & FINANCE HOLDING COMPANY
VVOS BURNING ROCK BIOTECH LIMITED
MESO VIVOS THERAPEUTICS INC
USAU MESOBLAST LIMITED
COE USA URANIUM
COLUMBIA EQUITY TRUST
INC.
- Sid Rajeev
Global Education Communities Corp. (TSX: GEC) - Rental Strength Drives...
Q2 results (ended February 2026) showed modest top-line growth but stronger profitability, with revenue rising 1% YoY but coming in 4% below expectations as 10% growth in the core rental segment—supported by recently completed projects—was partially offset by weaker non-core revenue. Despite the revenue miss, earnings outperformed, with EPS improving from a loss of ($0.02) to a profit of $0.04 (15% above estimates), driven by a 2.7 percentage point YoY expansion in gross margins to 68.3% and low...
Pliant Therapeutics Announces Presentation of Updated Data from the Ph...
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif., April 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the presentation of updat...
iCAUR V27 Secures CATARC L3 Off-Road Certification, Solidifying Its Ne...
iCAUR V27 Secures CATARC L3 Off-Road Certification, Solidifying Its New Energy Off-Road Capability with Robust Technology WUHU, China, April 18, 2026 (GLOBE NEWSWIRE) -- Recently, the iCAUR V27 officially obtained the L3 Off-Road Certification from CATARC (China Automotive Technology and Research Center). Based on real-world off-road scenarios, the certification covers extreme conditions such as cross-axle articulation, steep slopes, mud, and gravel roads, with rigorous evaluation standards for off-road capability, four-wheel-drive response, body rigidity, power system stability, and hand...
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed bett...
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world settingResults were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany. Paris, April 18, 2026. Sanofi's protein-based non-mRNA COVID-1...
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-1...
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe Première étude comparative de phase 4, randomisée, en double aveugle, permettant de comparer directement les profils de tolérance de ces vaccins chez les adultes dans un contexte réelLes résultats ont été présentés aujourd’hui au Congrès mondial de la Société européenne de microbi...
NYLI CBRE Global Infrastructure Megatrends Term Fund: 1 director
A director at NYLI CBRE Global Infrastructure Megatrends Term Fund bought 5,500 shares at 15.146USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
PyroGenesis Inc: 1 director
A director at PyroGenesis Inc sold 4,890,000 shares at 0.424CAD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Kontrolmatik Teknoloji Enerji Ve Muhendislik: 2 directors
Two Directors at Kontrolmatik Teknoloji Enerji Ve Muhendislik sold 78,518,092 shares at 10.000TRY. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Alpine Select AG: 2 directors
A director at Alpine Select AG sold 700 shares at 9.100CHF and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.